NASDAQ:NEO

NeoGenomics Stock Forecast, Price & News

$49.34
-0.20 (-0.40 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$48.80
Now: $49.34
$50.30
50-Day Range
$41.56
MA: $48.28
$54.34
52-Week Range
$25.19
Now: $49.34
$61.57
Volume671,746 shs
Average Volume1.02 million shs
Market Capitalization$5.78 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.79
NeoGenomics, Inc. is a clinical laboratory company, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
NeoGenomics logo

Industry, Sector and Symbol

Industry Testing laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NEO
CUSIPN/A
Phone(239) 768-0600
Employees1,700
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$408.83 million
Cash Flow$0.48 per share
Book Value$4.86 per share

Profitability

Net Income$8.01 million

Miscellaneous

Market Cap$5.78 billion
Next Earnings Date5/5/2021 (Confirmed)
OptionableOptionable

Headlines

NeoGenomics Is Ready to Turn Higher - RealMoney - RealMoney
April 16, 2021 |  realmoney.thestreet.com
NeoGenomics Is Ready to Turn Higher
April 16, 2021 |  finance.yahoo.com
NeoGenomics (NASDAQ:NEO) Stock Price Down 4%
March 25, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.55 out of 5 stars

Medical Sector

447th out of 2,021 stocks

Testing Laboratories Industry

1st out of 3 stocks

Analyst Opinion: 2.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$49.34
-0.20 (-0.40 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NEO News and Ratings via Email

Sign-up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NeoGenomics (NASDAQ:NEO) Frequently Asked Questions

Is NeoGenomics a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NeoGenomics stock.
View analyst ratings for NeoGenomics
or view top-rated stocks.

What stocks does MarketBeat like better than NeoGenomics?

Wall Street analysts have given NeoGenomics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NeoGenomics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is NeoGenomics' next earnings date?

NeoGenomics is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for NeoGenomics
.

How can I listen to NeoGenomics' earnings call?

NeoGenomics will be holding an earnings conference call on Wednesday, May 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) posted its earnings results on Wednesday, February, 24th. The medical research company reported $0.14 EPS for the quarter, topping the Zacks' consensus estimate of $0.06 by $0.08. The medical research company had revenue of $126 million for the quarter, compared to analysts' expectations of $123.45 million. NeoGenomics had a negative net margin of 1.16% and a positive trailing twelve-month return on equity of 0.71%. The business's revenue for the quarter was up 17.8% compared to the same quarter last year. During the same period last year, the business posted $0.06 EPS.
View NeoGenomics' earnings history
.

How has NeoGenomics' stock been impacted by COVID-19?

NeoGenomics' stock was trading at $24.78 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NEO shares have increased by 99.1% and is now trading at $49.34.
View which stocks have been most impacted by COVID-19
.

How often does NeoGenomics pay dividends? What is the dividend yield for NeoGenomics?

NeoGenomics declared a dividend on Tuesday, December 15th. Stockholders of record on Friday, December 18th will be given a dividend of $0.40 per share on Wednesday, December 30th. This represents a dividend yield of 3.13%. The ex-dividend date is Thursday, December 17th.
View NeoGenomics' dividend history
.

What price target have analysts set for NEO?

11 brokers have issued 1 year target prices for NeoGenomics' shares. Their forecasts range from $14.50 to $65.00. On average, they anticipate NeoGenomics' stock price to reach $49.32 in the next twelve months. This suggests that the stock has a possible downside of 0.0%.
View analysts' price targets for NeoGenomics
or view top-rated stocks among Wall Street analysts.

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the following people:
  • Douglas M. Van Oort, Executive Chairman & Chief Executive Officer
  • Steven G. Brodie, VP-Worldwide Pharma Services Operations
  • Kathryn B. McKenzie, Chief Financial Officer
  • Steven A. Ross, Chief Information Officer & General Counsel
  • Lawrence M. Weiss, Chief Medical Officer

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics CEO Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among NeoGenomics' employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of NeoGenomics' key competitors?

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology Group (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.21%), State of Alaska Department of Revenue (0.07%), Louisiana State Employees Retirement System (0.05%), Everence Capital Management Inc. (0.02%), NEXT Financial Group Inc (0.01%) and HMS Capital Management LLC (0.01%). Company insiders that own NeoGenomics stock include Bruce K Crowther, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends for NeoGenomics
.

Which institutional investors are selling NeoGenomics stock?

NEO stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, HMS Capital Management LLC, and Global Retirement Partners LLC. Company insiders that have sold NeoGenomics company stock in the last year include Bruce K Crowther, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lawrence Martin Weiss, Oort Douglas M Van, Robert J Shovlin, Steven C Jones, and William Bonello.
View insider buying and selling activity for NeoGenomics
or view top insider-selling stocks.

Which institutional investors are buying NeoGenomics stock?

NEO stock was bought by a variety of institutional investors in the last quarter, including Scout Investments Inc., Everence Capital Management Inc., Louisiana State Employees Retirement System, and NEXT Financial Group Inc.
View insider buying and selling activity for NeoGenomics
or or view top insider-buying stocks.

How do I buy shares of NeoGenomics?

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $49.34.

How much money does NeoGenomics make?

NeoGenomics has a market capitalization of $5.78 billion and generates $408.83 million in revenue each year. The medical research company earns $8.01 million in net income (profit) each year or $0.23 on an earnings per share basis.

How many employees does NeoGenomics have?

NeoGenomics employs 1,700 workers across the globe.

What is NeoGenomics' official website?

The official website for NeoGenomics is www.neogenomics.com.

Where are NeoGenomics' headquarters?

NeoGenomics is headquartered at 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at (239) 768-0600 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.